

| | | | | | | | |
|--|---|----|---|-----------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | | APPLICATION NO.: 10/644,052 | | ATTY. DOCKET NO.: C1037.70048US00 | |
| | | | | FILING DATE: August 19, 2003 | | CONFIRMATION NO.: 4791 | |
| | | | | APPLICANT: Arthur M. Krieg et al. | | | |
| | | | | GROUP ART UNIT: 1645 | | EXAMINER: Nina Archie | |
| Sheet | 1 | of | 3 | | | | |

U.S. PATENT DOCUMENTS

| Examiner's Initials * | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|--------------------------|-------------|----------------------|--------------|--|---|
| | | Number | Kind Code | | |
| | | 5,416,203 | | Letsinger | 05-16-1995 |
| | | 5,696,248 | | Peyman et al. | 12-09-1997 |
| | | 7,262,286 | B2 | Kandimala et al. | 08-28-2007 |
| | | 7,354,711 | B2 | Macfarlane | 04-08-2008 |
| | | 7,402,572 | B2 | Krieg et al. | 07-22-2008 |
| | | 7,410,975 | B2 | Lipford et al. | 08-12-2008 |
| | | 7,488,490 | B2 | Davis et al. | 02-10-2009 |
| | | 7,517,861 | B2 | Krieg et al. | 04-14-2009 |
| | | 7,524,828 | B2 | Krieg et al. | 09-08-2009 |
| | | 7,534,772 | B2 | Weiner et al. | 05-19-2009 |
| | | 7,566,703 | B2 | Krieg et al. | 07-28-2009 |
| | | 7,569,553 | B2 | Kreig | 08-04-2009 |
| | | 7,576,066 | B2 | Krieg | 08-18-2009 |
| | | 7,585,847 | B2 | Bratzler et al. | 09-08-2009 |
| | | 2002-0151518 | A1 | Agrawal et al. | 10-17-2002 |
| | | 2003-0129605 | A1 | Yu et al. | 07-10-2003 |
| | | 2005-0266015 | A1 | Clerici et al. | 12-01-2005 |
| | | 2006-0014713 | A1 | Agrawal et al. | 01-19-2006 |
| | | 2006-0094680 | A1 | Agrawal et al. | 05-04-2006 |
| | | 2006-0094681 | A1 | Agrawal et al. | 05-04-2006 |
| | | 2006-0287262 | A1 | Agrawal et al. | 12-21-2006 |
| | | 2007-0105801 | A1 | Agrawal et al. | 05-10-2007 |
| | | 2008-0113929 | A1 | Lipford et al. | 05-15-2008 |
| | | 2008-0152662 | A1 | Agrawal et al. | 06-26-2008 |
| | | 2008-0226649 | A1 | Schetter et al. | 09-18-2008 |
| | | 2009-0017021 | A1 | Davis et al. | 01-15-2009 |
| | | 2009-0060927 | A1 | Wagner et al. | 03-05-2009 |
| | | 2009-0137519 | A1 | Krieg et al. | 05-28-2009 |
| | | 2009-0142362 | A1 | Krieg et al. | 06-04-2009 |
| | | 2009-0155307 | A1 | Davis et al. | 06-18-2009 |
| | | 2009-0155212 | A1 | Bratzler et al. | 06-18-2009 |
| | | 2009-0191188 | A1 | Krieg et al. | 07-30-2009 |
| | | 2009-0202575 | A1 | Krieg et al. | 08-13-2009 |

| | |
|---------------|--------------------------------|
| /Nina Archie/ | DATE CONSIDERED: 10/21/2009 |
|---------------|--------------------------------|

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|---|-----------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | | APPLICATION NO.: 10/644,052 | ATTY. DOCKET NO.: C1037.70048US00 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | FILING DATE: August 19, 2003 | CONFIRMATION NO.: 4791 |
| | | | | APPLICANT: Arthur M. Krieg et al. | |
| | | | | GROUP ART UNIT: 1645 | EXAMINER: Nina Archie |
| Sheet | 2 | of | 3 | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|-----------------------|----------|-------------------------|-------------|-----------|---|--|-------------------|
| | | Office/Country | Number | Kind Code | | | |
| | | WO | 98/37919 | A1 | University of Iowa Research Foundation | 09-03-1998 | |
| | | WO | 2008/030455 | A2 | Coley Pharmaceutical Group, Inc. | 03-13-2008 | |
| | | WO | 2008/033432 | A2 | Coley Pharmaceutical Group, Inc. | 03-20-2008 | |
| | | WO | 2008/039538 | A2 | Coley Pharmaceutical Group, Inc. | 04-03-2008 | |
| | | WO | 2008/068638 | A2 | Coley Pharmaceutical GMBH | 06-12-2008 | |
| | | WO | 2008/139262 | A2 | Coley Pharmaceutical GMBH | 11-20-2008 | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|-----------------------|---------|---|-------------------|
| | | AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998: 525-43. | |
| | | BALLAS et al., Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 1;167(9):4878-86. | |
| | | BHAGAT et al., CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun. 2003 Jan 24;300(4):853-61. | |
| | | FATTHI et al., Oligonucleotides with novel, cationic backbone substituents: minoethylphosphonates. Nucleic Acids Res. 1994 Dec 11;22(24):5416-24. | |
| | | HARTMANN et al., Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41. | |
| | | KATAOKA et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. Jpn J Cancer Res. 1992 Mar;83(3):244-7. | |
| | | MARSHALL et al., Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol. 2003 Jun;73(6):781-92. | |
| | | McCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22;19(7-8):950-7. | |
| | | SAMANI et al., Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):129-36. | |
| | | UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel. 2003 Mar;6(2):204-17. | |
| | | VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):165-75. | |
| | | VOLLMER et al., Identification of a new class of CpG oligonucleotides capable of inducing both B cell proliferation and high IFN-alpha secretion from PBMC of HCV chronic carriers. Antiv Ther. 2002;7:L115. | |
| | | VOLLMER et al., Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J Leukoc Biol. 2004 Sep;76(3):585-93. Epub 2004 Jun 24. | |

| | |
|---------------|--------------------------------|
| /Nina Archie/ | DATE CONSIDERED: 10/21/2009 |
|---------------|--------------------------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|---|-----------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | | APPLICATION NO.: 10/644,052 | ATTY. DOCKET NO.: C1037.70048US00 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | FILING DATE: August 19, 2003 | CONFIRMATION NO.: 4791 |
| | | | | APPLICANT: Arthur M. Krieg et al. | |
| | | | | GROUP ART UNIT: 1645 | EXAMINER: Nina Archie |
| Sheet | 3 | of | 3 | | |

| | | |
|--|---|--|
| | VOLLMER, CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol. 2006 May-Aug;25(3-4):125-34. | |
| | VOLLMER, TLR9 in health and disease. Int Rev Immunol. 2006 May-Aug;25(3-4):155-81. | |
| | WEIGEL et al., CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003 Aug 1;9(8):3105-14. | |
| | WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7. | |
| | YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res. 1994 Aug;85(8):775-9. | |
| | YU et al., 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 2002 Oct 15;30(20):4460-9. | |
| | YU et al., Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem. 2001 Nov;9(11):2803-8. | |
| | YU et al., Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun. 2002 Sep 13;297(1):83-90. | |

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | |
|---------------|--------------------------------|
| /Nina Archie/ | DATE CONSIDERED: 10/21/2009 |
|---------------|--------------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.